A recent study examined data from more than 10,000 patients with ‘Biopsy Gleason Grade Group (GGG) 1,’ a diagnosis considered to be the lowest grade cancer. Researchers found that even among patients diagnosed using the most modern diagnostic approach, 8 percent of patients with GGG1 had high-risk prostate cancer. Two risk factors — high PSA levels and the presence of 50 percent or more positive biopsies from sampling — could help identify patients with GGG1 at greatest risk of aggressive prostate cancer and increased risk of death.
